Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia

Introduction: Naftopidil, approved initially in Japan, is an α1d-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). It is different from tamsulosin hydrochloride and silodosin, in that it has a higher affinity for...

Full description

Bibliographic Details
Main Authors: Mahavir Singh Griwan, Y. R. Karthikeyan, Mandeep Kumar, Bikram Jit Singh, Santosh Kumar Singh
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-01-01
Series:Urology Annals
Subjects:
Benign prostatic hyperplasia
LUTS
naftopidil
tamsulosin
Online Access:http://www.urologyannals.com/article.asp?issn=0974-7796;year=2014;volume=6;issue=3;spage=181;epage=186;aulast=Griwan

Internet

http://www.urologyannals.com/article.asp?issn=0974-7796;year=2014;volume=6;issue=3;spage=181;epage=186;aulast=Griwan

Similar Items